Here are the 10-K annual reports from Protagenic Therapeutics (PTIX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow PTIX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PTIX filings page.
Protagenic Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing PT00114, a synthetic form of TCAP-1, for stress-related neuropsychiatric and mood disorders including depression, anxiety, addiction and PTSD. PT00114 has completed single- and multiple-dose Phase I testing in healthy volunteers, with a Phase 2 study planned for late 2026 and an investigational new drug resubmission anticipated in 2026 to enable U.S. Phase IIa work.
During the year ended March 31, 2026, Protagenic completed and unwound a reverse merger with Phytanix Bio, so fiscal 2026 results consolidate Phytanix only through the unwind date, limiting year-to-year comparability. The company reported net income of $1.37 million for 2026 versus a prior-year net loss, but still has an accumulated deficit of $4.03 million and no product revenue. Management states cash resources are sufficient only until the end of the third quarter of 2026, and financial statements are prepared on a going concern basis.
The business depends heavily on an exclusive license from the University of Toronto for TCAP-related intellectual property, requiring a 2.5% royalty on future net sales and a share of any sublicense fees. Operations are lean, with two full-time and one part-time employees, and extensive use of contract research and manufacturing organizations.